Bederocin

Synonym(s): REP8839

Class: Aminoacyl-tRNA synthetase inhibitor (methionyl tRNA synthetase [MetRS] inhibitor)

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Protein synthesis inhibitor by inhibiting methionyl tRNA synthetase; active against MRSA and Streptococcus pyrogenes. Moderately active against Gram negatives.
Institute where first reported:	GSK, USA; Replidyne, Inc., (Cardiovascular Systems, Inc, USA)
Year first mentioned:	2004
Highest developmental phase:	Phase 1
Development status:	Discontinued
Reason Dropped:	Replidyne suspended development of this compound due to need of additional investment (S1)

Chemical structure(s):
Canonical SMILES:	CC1=C(CNCCCNC2=CC(=O)C3=C(C=CC=C3)N2)SC(=C1Br)C(=C)F
Isomeric SMILES:	CC1=C(SC(=C1Br)C(=C)F)CNCCCNC2=CC(=O)C3=CC=CC=C3N2
InChI:	InChI=1S/C20H21BrFN3OS/c1-12-17(27-20(13(2)22)19(12)21)11-23-8-5-9-24-18-10-16(26)14-6-3-4-7-15(14)25-18/h3-4,6-7,10,23H,2,5,8-9,11H2,1H3,(H2,24,25,26)
InChI Key:	BGJMKHPWCFXMOW-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/9868368

External links:
Guide to Pharmacology:	bederocin
Main Source:	https://pubmed.ncbi.nlm.nih.gov/19015366/
Citation:	http://adis.springer.com/drugs/800025207